BACKGROUND AND OBJECTIVES:CKD is common among older patients. This article assesses long-term renal and cardiovascular outcomes in older high-risk hypertensive patients, stratified by baseline estimated GFR (eGFR), and long-term outcome efficacy of 5-year first-step treatment with amlodipine or lisinopril, each compared with chlorthalidone. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a long-term post-trial follow-up of hypertensive participants (n=31,350), aged ≥55 years, randomized to receive chlorthalidone, amlodipine, or lisinoprilfor 4-8 years at 593 centers. Participants were stratified by baseline eGFR (ml/min per 1.73 m(2)) as follows: normal/increased (≥90; n=8027), mild reduction (60-89; n=17,778), and moderate/severe reduction (<60; n=5545). Outcomes were cardiovascular mortality (primary outcome), total mortality, coronary heart disease, cardiovascular disease, stroke, heart failure, and ESRD. RESULTS: After an average 8.8-year follow-up, total mortality was significantly higher in participants with moderate/severe eGFR reduction compared with those with normal and mildly reduced eGFR (P<0.001). In participants with an eGFR <60, there was no significant difference in cardiovascular mortality between chlorthalidone and amlodipine (P=0.64), or chlorthalidone and lisinopril (P=0.56). Likewise, no significant differences were observed for total mortality, coronary heart disease, cardiovascular disease, stroke, or ESRD. CONCLUSIONS:CKD is associated with significantly higher long-term risk of cardiovascular events and mortality in older hypertensive patients. By eGFR stratum, 5-year treatment with amlodipine or lisinopril was not superior to chlorthalidone in preventing cardiovascular events, mortality, or ESRD during 9-year follow-up. Because data on proteinuria were not available, these findings may not be extrapolated to proteinuric CKD.
RCT Entities:
BACKGROUND AND OBJECTIVES: CKD is common among older patients. This article assesses long-term renal and cardiovascular outcomes in older high-risk hypertensivepatients, stratified by baseline estimated GFR (eGFR), and long-term outcome efficacy of 5-year first-step treatment with amlodipine or lisinopril, each compared with chlorthalidone. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a long-term post-trial follow-up of hypertensiveparticipants (n=31,350), aged ≥55 years, randomized to receive chlorthalidone, amlodipine, or lisinopril for 4-8 years at 593 centers. Participants were stratified by baseline eGFR (ml/min per 1.73 m(2)) as follows: normal/increased (≥90; n=8027), mild reduction (60-89; n=17,778), and moderate/severe reduction (<60; n=5545). Outcomes were cardiovascular mortality (primary outcome), total mortality, coronary heart disease, cardiovascular disease, stroke, heart failure, and ESRD. RESULTS: After an average 8.8-year follow-up, total mortality was significantly higher in participants with moderate/severe eGFR reduction compared with those with normal and mildly reduced eGFR (P<0.001). In participants with an eGFR <60, there was no significant difference in cardiovascular mortality between chlorthalidone and amlodipine (P=0.64), or chlorthalidone and lisinopril (P=0.56). Likewise, no significant differences were observed for total mortality, coronary heart disease, cardiovascular disease, stroke, or ESRD. CONCLUSIONS: CKD is associated with significantly higher long-term risk of cardiovascular events and mortality in older hypertensivepatients. By eGFR stratum, 5-year treatment with amlodipine or lisinopril was not superior to chlorthalidone in preventing cardiovascular events, mortality, or ESRD during 9-year follow-up. Because data on proteinuria were not available, these findings may not be extrapolated to proteinuric CKD.
Authors: Lawrence J Appel; Jackson T Wright; Tom Greene; Lawrence Y Agodoa; Brad C Astor; George L Bakris; William H Cleveland; Jeanne Charleston; Gabriel Contreras; Marquetta L Faulkner; Francis B Gabbai; Jennifer J Gassman; Lee A Hebert; Kenneth A Jamerson; Joel D Kopple; John W Kusek; James P Lash; Janice P Lea; Julia B Lewis; Michael S Lipkowitz; Shaul G Massry; Edgar R Miller; Keith Norris; Robert A Phillips; Velvie A Pogue; Otelio S Randall; Stephen G Rostand; Miroslaw J Smogorzewski; Robert D Toto; Xuelei Wang Journal: N Engl J Med Date: 2010-09-02 Impact factor: 91.245
Authors: Vlado Perkovic; Toshiharu Ninomiya; Hisatomi Arima; Martin Gallagher; Meg Jardine; Alan Cass; Bruce Neal; Stephen Macmahon; John Chalmers Journal: J Am Soc Nephrol Date: 2007-09-05 Impact factor: 10.121
Authors: S Reungjui; H Hu; W Mu; C A Roncal; B P Croker; J M Patel; T Nakagawa; T Srinivas; K Byer; J Simoni; D Wesson; V Sitprija; R J Johnson Journal: Kidney Int Date: 2007-10-10 Impact factor: 10.612
Authors: Mahboob Rahman; Sara Pressel; Barry R Davis; Chuke Nwachuku; Jackson T Wright; Paul K Whelton; Joshua Barzilay; Vecihi Batuman; John H Eckfeldt; Michael A Farber; Stanley Franklin; Mario Henriquez; Nelson Kopyt; Gail T Louis; Mohammad Saklayen; Carole Stanford; Candace Walworth; Harry Ward; Thomas Wiegmann Journal: Ann Intern Med Date: 2006-02-07 Impact factor: 25.391
Authors: Sankar D Navaneethan; Jason Roy; Kelvin Tao; Carolyn S Brecklin; Jing Chen; Rajat Deo; John M Flack; Akinlolu O Ojo; Theodore J Plappert; Dominic S Raj; Ghulam Saydain; James H Sondheimer; Ruchi Sood; Susan P Steigerwalt; Raymond R Townsend; Raed A Dweik; Mahboob Rahman Journal: J Am Soc Nephrol Date: 2015-09-18 Impact factor: 10.121
Authors: Suzanne Oparil; Barry R Davis; William C Cushman; Charles E Ford; Curt D Furberg; Gabriel B Habib; L Julian Haywood; Karen Margolis; Jeffrey L Probstfield; Paul K Whelton; Jackson T Wright Journal: Hypertension Date: 2013-03-25 Impact factor: 10.190
Authors: Talar W Markossian; Holly J Kramer; Nicholas J Burge; Ivan V Pacold; David J Leehey; Zhiping Huo; Julia Schneider; Benjamin Ling; Kevin T Stroupe Journal: Clin Kidney J Date: 2019-01-27